Allspring Global Investments Holdings LLC Sells 1,681 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 9.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,437 shares of the biopharmaceutical company’s stock after selling 1,681 shares during the period. Allspring Global Investments Holdings LLC’s holdings in TG Therapeutics were worth $465,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Bleakley Financial Group LLC bought a new stake in shares of TG Therapeutics during the 4th quarter worth $245,000. Oppenheimer & Co. Inc. bought a new stake in shares of TG Therapeutics during the 3rd quarter worth $759,000. Segall Bryant & Hamill LLC bought a new stake in shares of TG Therapeutics during the 3rd quarter worth $1,225,000. Barclays PLC raised its stake in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after purchasing an additional 158,323 shares during the period. Finally, Principal Financial Group Inc. raised its stake in shares of TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after purchasing an additional 725,371 shares during the period. 58.58% of the stock is currently owned by institutional investors.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at $20,313,443.28. The trade was a 1.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 10.50% of the company’s stock.

TG Therapeutics Stock Down 6.0 %

TGTX stock opened at $29.02 on Tuesday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $4.52 billion, a PE ratio of -290.17 and a beta of 2.26. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $36.84. The stock has a 50-day simple moving average of $30.96 and a two-hundred day simple moving average of $27.90.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. Finally, TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.